RNS Number:6434Q
ReGen Therapeutics PLC
08 October 2003


ReGen Therapeutics Plc


8th October 2003


ColostrininTM Clinical Study to be published in Journal of Alzheimer's Disease


ReGen Therapeutics Plc ("ReGen" or the "Company"), a company developing a
potential treatment for Alzheimer's disease, announces that a manuscript
reviewing the full results of its clinical study RG-010 has been accepted in its
final form for publication in the Journal of Alzheimer's Disease (the
"Journal"). The publishers of the Journal advise that the article will appear in
their February 2004 edition.


Clinical study RG-010 compared ColostrininTM with a placebo in the treatment of
106 patients with mild or moderate Alzheimer's disease. Headline results at
completion of the 30-week study were as follows:


* Approximately 40% of patients on ColostrininTM were stabilised or
  improved after 15 weeks of therapy, based on an Analysis of Overall Response


* 33% of patients continued to show stabilisation or improvement after 30
  weeks of treatment, although levels of benefit were slightly higher at the
  15-week stage of the trial


* Efficacy demonstrated in both mild and moderate symptom groups, with
  greatest effects seen in earlier stages of the disease


* No drug-related Serious Adverse Events or safety concerns were observed
  during the trial


Percy Lomax, ReGen's Executive Chairman commented "We are pleased that the full
results of the study will be published in this international peer reviewed
journal that focuses on all aspects of the management of Alzheimer's disease. We
believe that the publication of the article will communicate the potential of
ColostrininTM as a safe and effective therapy for Alzheimer's disease to a much
wider audience, including potential development and/or marketing partners".


Further information:

Andrew Marshall
Marshall Robinson Roe
Tel No: 020 7960 6007




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RESFSFFUWSDSESS